Miklos Acs1, Michael Gerken2, Ivana Gajic3, Max Mayr3, Jozef Zustin4,5, Pompiliu Piso3. 1. Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany. miklos.acs@barmherzige-regensburg.de. 2. Tumor Center-Institute for Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany. 3. Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany. 4. Gerhard Domagk Institute of Pathology, University Medical Center Muenster, Muenster, Germany. 5. Institute of Pathology Regensburg, Regensburg, Germany.
Abstract
PURPOSE: This single-center study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM). METHODS: Prospectively collected data from a single institution data registry was retrospectively investigated. Eighty-four patients with primary malignant peritoneal mesothelioma underwent CRS and HIPEC with cisplatin and doxorubicin either for 60 min or 90 min of duration from 2011 to 2021. The primary endpoint was overall survival. The secondary endpoint was the evaluation of prognostic factors for overall survival. The tertiary endpoint was to assess the effect of neoadjuvant chemotherapy on survival. RESULTS: The median follow-up was 5.0 years (95%-CI 4.6-5.5). The median age was 59.2 years (IQR: 47-66). Eighty-two patients (97.6%) had epithelioid tumors. The median peritoneal cancer index was 18.0 (IQR: 13-27). Sixty-six patients (78.6%) had complete or near-complete cytoreduction (CCR 0 or CCR 1). Seventy patients (83.3%) received HIPEC for 60 min and 14 patients (16.7%) received it for 90 min. Twenty-two patients (26.2%) had grade 3 to 4 complications. Acute kidney injury (AKI) stage I-III occurred in 30 (35.7%) patients. Three patients (3.6%) died perioperatively. The overall median survival was 38.4 months (95%-CI 23.6-54.3), and the 5-year survival rate was 42%. Survival was independently associated with age, female gender, and thrombocytosis. Preoperative chemotherapy did not emerge as an adverse prognostic factor. CONCLUSION: In well-selected patients with DMPM, prolonged survival is achievable with CRS and HIPEC in specialized centers.
PURPOSE: This single-center study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM). METHODS: Prospectively collected data from a single institution data registry was retrospectively investigated. Eighty-four patients with primary malignant peritoneal mesothelioma underwent CRS and HIPEC with cisplatin and doxorubicin either for 60 min or 90 min of duration from 2011 to 2021. The primary endpoint was overall survival. The secondary endpoint was the evaluation of prognostic factors for overall survival. The tertiary endpoint was to assess the effect of neoadjuvant chemotherapy on survival. RESULTS: The median follow-up was 5.0 years (95%-CI 4.6-5.5). The median age was 59.2 years (IQR: 47-66). Eighty-two patients (97.6%) had epithelioid tumors. The median peritoneal cancer index was 18.0 (IQR: 13-27). Sixty-six patients (78.6%) had complete or near-complete cytoreduction (CCR 0 or CCR 1). Seventy patients (83.3%) received HIPEC for 60 min and 14 patients (16.7%) received it for 90 min. Twenty-two patients (26.2%) had grade 3 to 4 complications. Acute kidney injury (AKI) stage I-III occurred in 30 (35.7%) patients. Three patients (3.6%) died perioperatively. The overall median survival was 38.4 months (95%-CI 23.6-54.3), and the 5-year survival rate was 42%. Survival was independently associated with age, female gender, and thrombocytosis. Preoperative chemotherapy did not emerge as an adverse prognostic factor. CONCLUSION: In well-selected patients with DMPM, prolonged survival is achievable with CRS and HIPEC in specialized centers.
Authors: C Cao; T D Yan; M Deraco; D Elias; O Glehen; E A Levine; B J Moran; D L Morris; T C Chua; P Piso; P H Sugarbaker Journal: Ann Oncol Date: 2011-11-04 Impact factor: 32.976
Authors: Tristan D Yan; Marcello Deraco; Dominique Elias; Olivier Glehen; Edward A Levine; Brendan J Moran; David L Morris; Terence C Chua; Pompiliu Piso; Paul H Sugarbaker Journal: Cancer Date: 2010-11-18 Impact factor: 6.860
Authors: Martin Lehnert; Klaus Kraywinkel; Evelyn Heinze; Thorsten Wiethege; Georg Johnen; Julia Fiebig; Thomas Brüning; Dirk Taeger Journal: Cancer Causes Control Date: 2016-12-27 Impact factor: 2.506
Authors: G Carteni; C Manegold; G Martin Garcia; S Siena; C C Zielinski; D Amadori; Y Liu; J Blatter; C Visseren-Grul; R Stahel Journal: Lung Cancer Date: 2008-11-29 Impact factor: 5.705
Authors: Tristan D Yan; Marcello Deraco; Dario Baratti; Shigeki Kusamura; Dominique Elias; Olivier Glehen; François N Gilly; Edward A Levine; Perry Shen; Faheez Mohamed; Brendan J Moran; David L Morris; Terence C Chua; Pompiliu Piso; Paul H Sugarbaker Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544